LRP6 and non-small cell lung carcinoma: In this study, we identified NSCLC patients harboring UBL biological process gene (ABL1, APC, LRP6, FUBP1, KEAP1, and TOP2) mutations, and this information could be used to stratify patients who might respond to the immune checkpoint inhibitor atezolizumab.